	US 7,585,858 B2
	N-sulfonylcarboximidamide apoptosis promoters
Steven W. Elmore, Gurnee, Ill. (US); Milan Bruncko, Green Oaks, Ill. (US); and Cheol-Min Park, Gurnee, Ill. (US)
Assigned to Abbott Laboratories, Abbott Park, Ill. (US)
Filed on May 26, 2005, as Appl. No. 11/138,717.
Claims priority of provisional application 60/574500, filed on May 26, 2004.
Prior Publication US 2005/0272744 A1, Dec. 08, 2005
Int. Cl. A61K 31/5377 (2006.01); A61K 31/451 (2006.01); C07D 211/14 (2006.01); C07D 211/48 (2006.01); C07D 211/70 (2006.01); C07D 413/12 (2006.01); A61K 31/495 (2006.01); C07D 295/195 (2006.01)

U.S. Cl. 514—235.5 [514/326; 514/331; 514/255.01; 514/235.8; 544/129; 544/121; 544/392; 544/398; 546/213; 546/216; 546/231]

4 Claims

1. A compound of formula (I)

or a therapeutically acceptable salt thereof, wherein

A is phenyl;

R¹is selected from the group consisting of alkyl, cyano, halo, haloalkyl and nitro;

R²is —NR⁵R⁶;

R³is hydrogen;

R⁴is piperidinyl;

R⁵is hydrogen and and R⁶is arylsulfanylalkyl, the alkyl part of which can be further optionally substituted with morpholinyl or NR^aR^b, wherein R^aand R^bare alkyl; and

R¹⁵is selected from the group consisting of hydrogen, alkoxy, alkyl, and halo.